[01] Sujata Sarkar, Department of Radiotherapy, Batra Hospital and Medical Research Centre (BHMRC), New Delhi, India. [02] Irfan Bashir, Department of Radiotherapy, Batra Hospital and Medical Research Centre (BHMRC), New Delhi, India. [03] Roopesh Reddy Yotham, Department of Radiotherapy, Batra Hospital and Medical Research Centre (BHMRC), New Delhi, India.

Hemangiopericytoma (HPC) is a tumor that arises from the pericytes of capillaries. It is a variety of soft tissue sarcoma. HPC is often asymptomatic in early stages. HPCs can be either benign or malignant. Malignant HPCs can metastasize or spread to other areas in the body, primarily the lungs and bones. HPCs are one of the least common intracranial tumors, accounting for less than 1% of cases reported. Pituitary fossa is one of the rarest sites among all cases reported. HPCs are positive for vimentin, negative for desmin, CD31, cytokeratin, S-100. Recently, STAT6 positivity has been shown to be very specific of HPC. Even with appropriate treatment, 80% of HPCs recur and 23% metastasize, making it rare yet very aggressive tumor. The high recurrence rate makes it difficult for patient to undergo repeated surgeries, especially in HPCs of central nervous system (CNS). Here, we are reporting a case of Hemangiopericytoma in pituitary fossa in a 55 year old male, which recurred to a large size of > 4 cm within a year of previous surgery. Due to its large size and close proximity to optic chiasm, both surgery and radiotherapy were critical for this patient. Patient was treated with radiotherapy by volumetric modulated arc technique (VMAT). VMAT has high efficacy in treating tumors that are in close proximity to critical tissues with least toxicity. Radiotherapy improves local control and increases overall survival irrespective of previous surgical outcome. Following radiotherapy, his symptoms subsided and no disease progression is seen on 3 months follow up.

Hemangiopericytoma, Pituitary Fossa, Radiotherapy, VMAT

[01] Soyuer S, Chang EL, Selek U, McCutcheon IE, Maor MH. Intracranial meningeal hemangiopericytoma: the role of radiotherapy: report of 29 cases and review of the literature. Cancer. 2004; 100: 1491-1497. [02] Kewei Wang, Fei Mei, Sisi Wu, et al. Hemangiopericytoma: Incidence, Treatment, and Prognosis Analysis Based on SEER Database BioMed Research International / 2020 / Article ID 2468320 | https://doi.org/10.1155/2020/2468320 [03] Louis D, Ohgaki H, Wiestler O, Cavanee W. World Health Organization (WHO) classification of tumours of the central nervous system. Vol. 1. Revised. 4th ed. Geneva, Switzerland: WHO press; 2016. [04] McKeever PE. Immunohistology of the nervous system. In: Dabbs D, ed. Diagnostic Immunohistochemistry. 2nd ed. Philadelphia: Churchill Livingstone; 2006: 746-816. [05] E. Tani, J. Wejde, K. Astrom, I. L. Wingmo, O. Larsson, and F. Haglund, “FNA cytology of solitary fibrous tumors and the diagnostic value of STAT6 immunocytochemistry,” Cancer Cytopathology, vol. 126, no. 1, pp. 36–43, 2018. [06] Hanau CA, Miettinen M. Solitary fibrous tumor: histological and immunohistochemical spectrum of benign and malignant variants presenting at different sites. Hum Pathol. 1995; 26:440–449. [PubMed] [Google Scholar] [07] S. Ohba, K. Murayama, Y. Nishiyama et al., “Clinical and radiographic features for differentiating solitary fibrous tumor/hemangiopericytoma from meningioma,” World Neurosurgery, vol. 130, pp. e383–e392, 2019. View at: Publisher Site | Google Scholar [08] M. Koch, G. P. Nielsen, and S. S. Yoon, “Malignant tumors of blood vessels: angiosarcomas, hemangioendotheliomas, and hemangioperictyomas,” Journal of Surgical Oncology, vol. 97, no. 4, pp. 321–329, 2008. [09] Matthias E Ernst, Aimée Hiller, Regina Reimann, Carlo Serra et al, "Hemangiopericytoma mimicking a pituitary adenoma: a case report" Endocrine Abstracts (2019) 63 P 738 | DOI: 10.1530/endoabs. 63. P 738. [10] J. S. Brooks and S. Lee, “Contemporary diagnostics: sarcoma pathology update,” Journal of Surgical Oncology, vol. 111, no. 5, pp. 513–519, 2015. [11] M. Krengli, T. Cena, T. Zilli et al., “Radiotherapy in the treatment of extracranial hemangiopericytoma/solitary fibrous tumor: study from the Rare Cancer Network,” Radiotherapy and Oncology, vol. 144, pp. 114–120, 2020. [12] Ecker RD, Marsh WR, Pollock BE, Kurtkaya-Yapicier O, McClelland R, Scheithauer BW, et al. Hemangiopericytoma in the central nervous system: treatment, pathological features, and long-term follow up in 38 patients. J Neurosurg. 2003; 98: 1182–1187. [PubMed] [Google Scholar] [13] S. H. Jeon, S. H. Park, J. W. Kim, C. K. Park, S. H. Paek, and I. H. Kim, “Efficacy of adjuvant radiotherapy in the intracranial hemangiopericytoma,” Journal of Neuro-Oncology, vol. 137, no. 3, pp. 567–573, 2018. [14] A. M. Stessin, C. Sison, J. Nieto, M. Raifu, and B. Li, “The role of postoperative radiation therapy in the treatment of meningeal hemangiopericytoma-experience from the SEER database,” International Journal of Radiation Oncology • Biology • Physics, vol. 85, no. 3, pp. 784–790, 2013. [15] Guthrie BL, Ebersold MJ, Scheithauer BW, Shaw EG. Meningeal hemangiopericytoma: histopathological features, treatment, and long-term follow-up of 44 cases. Neurosurgery. 1989; 25: 514–522. [PubMed] [Google Scholar] [16] Ghia AJ, Chang EL, Allen PK, Mahajan A, Penas-Prado M et al. "Intracranial Hemangiopericytoma: Patterns of Failure and the Role of Radiation Therapy". Neurosurgery. 2013 Oct; 73 (4): 624-30; discussion 630-1. [17] T. Akman, A. Alacacioglu, D. Dolek et al., “Malign recurrence of primary chest wall hemangiopericytoma in the lung after four years: a case report and review of the literature,” Case Reports in Oncological Medicine, vol. 2014, Article ID 470268, 4 pages, 2014. [18] S. J. Lee, S. T. Kim, S. H. Park et al., “Successful use of pazopanib for treatment of refractory metastatic hemangiopericytoma,” Clinical Sarcoma Research, vol. 4, no. 1, p. 13, 2014. [19] M. Delgado, E. Perez-Ruiz, J. Alcalde, D. Perez, R. Villatoro, and A. Rueda, “Anti-angiogenic treatment (sunitinib) for disseminated malignant haemangiopericytoma: a case study and review of the literature,” Case Reports in Oncology, vol. 4, no. 1, pp. 55–59, 2011. [20] S. Stacchiotti, N. Simeone, S. Lo Vullo et al., “Activity of axitinib in progressive advanced solitary fibrous tumour: results from an exploratory, investigator-driven phase 2 clinical study,” European Journal of Cancer, vol. 106, pp. 225–233, 2019.